PR-022 (Paragon Therapeutics)

N/A

Report date: 2025/03/11 14:53:10

Base Information

Drug NamePR-022 (Paragon Therapeutics)
Drug Alias NamePR-022PR022SPY130SPY-130
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsTumor necrosis factor superfamily member 15 inhibitors
TargetsIntegrin alpha-4/beta-7Tumor necrosis factor superfamily member 15
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesParagon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSpyre Therapeutics IncParagon Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInflammatory Bowel Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A